

**Anti-Gelsolin (human)**

**Mouse monoclonal antibody**

Subclass: IgG1/k

CAT. NO.

**ABS 017-20**

Clone: 20

---

SPECIFICITY	ABS 017-20 binds human gelsolin
IMMUNOGEN	Gelsolin purified from human plasma
TESTED APPLICATIONS	ELISA, WB, IHC, IF
SPECIES REACTIVITY (POSITIVE)	Human
SPECIES REACTIVITY (NEGATIVE)	Not determined
EPITOPE SPECIFICITY	Not determined

---

**PRESENTATION**

Content:	Available in 400 µL and 1 mL size. 1 mg/mL +/- 15%. See Certificate of Analysis for details.
Preparation:	Protein-A purified
Form:	Liquid
Solvent:	0.01 M phosphate buffer, pH 7.4, containing 0.5 M NaCl and 15 mM sodium azide
Storage:	4-8°C without exposure to light. No precautions necessary during handling.

---

**APPLICATION**

**ELISA:** ABS 017-20 does not work as capture antibody in sandwich ELISA.

**WB:** ABS 017-20 can be used in Western blotting.

**IHC:** ABS 017-20 can be used in Immunohistochemistry.

**IF:** ABS 017-20 can be used in Immunofluorescence.

**TARGET**

Gelsolin participates in the extracellular actin scavenger system, binding actin and disaggregating filamentous actin released from dying cells. Actin monomers are then transferred to Gc-globulin. The plasma concentration of gelsolin is reduced in conditions of major actin release, such as acute liver failure, major trauma and rhabdomyolysis, where multi-organ failure is a risk. It has been suggested that gelsolin, like Gc-globulin, can be a prognostic factor in these conditions.

**REFERENCES**

**CONDITIONS**

Unless otherwise marked, all products are for research use only. Not for use in diagnostic procedures. Not for use in human therapeutic applications. For in vitro use or further manufacture only. The information and product are offered without guarantee as the ultimate conditions of use are beyond our control. The foregoing is in lieu of all warranties, expressed or implied, including implied warranties of merchantability and fitness for a particular purpose. In no event shall BioPorto Diagnostics A/S be responsible for loss of profits or indirect consequential losses resulting from use of its products.